NRX Pharmaceuticals annual stock-based compensation
2020
2021
2022
2023
2024
2025
NRX Pharmaceuticals Stock-Based Compensation Growth & History (NRXP)
NRX Pharmaceuticals's stock-based compensation was $228,000 for fiscal 2025.
View full NRX Pharmaceuticals company overviewNRX Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $228,000 | −$258,000 | −53.09% |
| 2024 | 2024-12-31 | $486,000 | $99,000 | +25.58% |
| 2023 | 2023-12-31 | $387,000 | −$3.2M | −89.33% |
| 2022 | 2022-12-31 | $3.6M | −$4.2M | −53.40% |
| 2021 | 2021-12-31 | $7.8M | $7.1M | +966.44% |
| 2020 | 2020-12-31 | $730,000 | — | — |
NRX Pharmaceuticals quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $139,000 | $72,000 | +107.46% |
| Q1 2026 | 2026-03-31 | $151,000 | $139,000 | +1158.33% |
| Q4 2025 | 2025-12-31 | $81,000 | $38,000 | +88.37% |
| Q3 2025 | 2025-09-30 | $68,000 | −$36,000 | −34.62% |
| Q2 2025 | 2025-06-30 | $67,000 | −$30,000 | −30.93% |
| Q1 2025 | 2025-03-31 | $12,000 | −$230,000 | −95.04% |
| Q4 2024 | 2024-12-31 | $43,000 | — | — |
| Q3 2024 | 2024-09-30 | $104,000 | −$247,000 | −70.37% |
| Q2 2024 | 2024-06-30 | $97,000 | −$447,000 | −82.17% |
| Q1 2024 | 2024-03-31 | $242,000 | −$453,000 | −65.18% |
| Q3 2023 | 2023-09-30 | $351,000 | −$190,000 | −35.12% |
| Q2 2023 | 2023-06-30 | $544,000 | −$443,000 | −44.88% |
| Q1 2023 | 2023-03-31 | $695,000 | −$639,000 | −47.90% |
| Q4 2022 | 2022-12-31 | $766,000 | −$804,000 | −51.21% |
| Q3 2022 | 2022-09-30 | $541,000 | −$1.0M | −65.32% |
| Q2 2022 | 2022-06-30 | $987,000 | −$3.3M | −76.96% |
| Q1 2022 | 2022-03-31 | $1.3M | $962,000 | +258.60% |
| Q4 2021 | 2021-12-31 | $1.6M | — | — |
| Q3 2021 | 2021-09-30 | $1.6M | $1.4M | +717.83% |
| Q2 2021 | 2021-06-30 | $4.3M | $4.2M | +4482.41% |
| Q1 2021 | 2021-03-31 | $372,000 | — | — |
| Q3 2020 | 2020-09-30 | $190,749 | — | — |
| Q2 2020 | 2020-06-30 | $93,466 | — | — |
NRX Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, NRX Pharmaceuticals's stock-based compensation decreased from $730,000 to $228,000, a change of −$502,000. The latest reported quarter, Q2 2026, shows $139,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NRX Pharmaceuticals source filings ↗